Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck will pay $400 million upfront and up to $1.73 billion in milestones for rights to SPR2015, an oral KRAS G12D cancer drug candidate. The company said the deal will result in a $400 million pre-tax charge in third-quarter 2026 results.
Merck NYSE:MRK said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.The deal underscores Merck's efforts to broaden its cancer drug pipeline as it prepares for p…